Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 12;24(6):1106–1116. doi: 10.1038/mt.2016.60

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

PMC Copyright notice

In vivo effects of P19 and P1- C/EBPα-saRNA. (a) P19- and P1-conjugated C/EBPα-saRNA aptamers were injected in PANC-1 engrafted mice via tail vein injection at 100 and 250 pmol. Tumor size was calculated by the formula 0.52 × length × width × width. Data are presented as the mean ± SD (n = 4 each group) (b) Tumor growth was monitored by evaluating bioluminescence before the first injection and 1 week after the last injection. The photons (left) and bioluminescent signal changes (right) were quantified. (c) Bioluminescent images of the xenografts are a representative of each treatment groups. (d) Comparison of the antitumor effect of C/EBPα-saRNA with gemcitabine. P19-conjugated C/EBPα-saRNA aptamers were injected in PANC-1 engrafted mice by tail vein injection at 1 nmol. Gemcitabine were injected by i.p. at 3 mg on day 5 and 7 for 4 weeks. Data are presented as the mean ± SD (n = 6 each group) (e) The antitumor effects in gemcitabine-resistant AsPC-1 cells in vivo were assessed. P19-conjugated C/EBPα-saRNA aptamers were injected in AsPC-1-engrafted mice by tail vein injection at 1 nmol. Data are presented as the mean ± SD (PBS: n = 6, P19-CEBP: n = 5, P19-Scr: n = 3, gemcitabine: n = 3). Tumor growth was monitored by evaluating bioluminescence before the first injection and 1 week after the last injection. The percentage of the cells that had metastasized to the ascites was measured. (f) To assess cytotoxicity following gemcitabine treatment, the blood parameter for hemoglobin, white blood cell count, platelets, and neutrophils were measured. Data are presented as the mean ± SD (n = 6 each group).